Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University General Hospital of Patras | OTHER |
Not provided
Not provided
Not provided
The purpose of the study is to determine the feasibility, safety and efficacy of administering rapidly-generated donor-derived pentavalent-specific T cells (Penta-STs) to mediate antiviral and antifungal activity in hematopoietic stem cell transplant (HSCT) recipients with AdV, EBV, CMV, BKV or Aspergillus fumigatus (AF) infection/ reactivation or with active disease.
Reconstitution of anti-viral and antifungal immunity by donor-derived antigen-specific T cells has shown promise in preventing and treating infections with CMV, or/and EBV, or/and AdV or/and BKV, HHV6 or/and AF post-transplant. However, the broader implementation of T cell immunotherapy using conventional protocols is limited and until today it was practically impossible for Greece by the cost, the complexity and the time required for virus-specific T cells (VSTs) production and by the antigenic competition between different antigens, which limits the spectrum of viruses that can be targeted in a single T cell product.
In this trial, the investigators will evaluate the feasibility, safety and efficacy of donor-derived Penta-STs infusion to allogeneic HSCT recipients with confirmed AdV, EBV, CMV, BKV and AF infection.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Penta-STs | Experimental | Patients will receive penta-STs in a single infusion. If they have a partial response or receive therapy post-infusion which could ablate the infused T cells they are eligible to receive up to 2 additional doses from 28 days after their first dose. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pentavalent-specific T cells (penta-STs) | Biological | Patients will receive penta-STs in a single infusion. If they have a partial response or receive therapy post-infusion which could ablate the infused T cells they are eligible to receive up to 2 additional doses from 28 days after their first dose. |
| Measure | Description | Time Frame |
|---|---|---|
| Acute GvHD | The safety of cell therapy with penta-STs will be assessed according to acute and chronic GvHD grades III-IV | Within 6 weeks post the last dose of penta-STs |
| Chronic GvHD | The safety of cell therapy with penta-STs will be assessed according to acute and chronic GvHD grades III-IV | Within 6 months post the last dose of penta-STs |
| Infusion-related adverse events | The safety of cell therapy with penta-STs will be assessed according to grades ≥3 infusion-related adverse events | Within 30 days of the last dose of penta-STs |
| Non hematological, adverse events | The safety of cell therapy with penta-STs will be assessed according to grades ≥3 non hematological, adverse events within 30 days of the last penta-ST dose, which are not due to the preexisting infection/comorbidities or the original malignancy | Within 30 days of the last dose of penta-STs |
| Resolution of infection - 1 | The efficacy of penta-STs will be determined based on the reduction/elimination of pathogen load in patients with infections | 12 weeks post the last dose of penta-STs |
| Resolution of infection - 2 | The efficacy of penta-STs will be determined based on the amelioration/elimination of clinical symptoms in patients with viral disease | 12 weeks post the last dose of penta-STs |
| Antiviral immunity |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Evangelia Yannaki, MD | George Papanicolaou Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University General Hospital of Patras | Pátrai | Greece | ||||
| George Papanikolaou Hospital - Gene and Cell Therapy Center- Hematology Dpt- Hematopoietic Stem Cell Transplant Center |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Patients from Hematology Department- Hematopoietic Stem Cell Transplantation Unit, George Papanikolaou Hospital and Bone Marrow Transplantation Unit of the University Hospital of Patras will be eligible to receive penta-STs as treatment for infection of one or more of the target-pathogens or for increasing pathogen load in two consecutive timepoints, following any type of allogeneic transplant.
If patients are receiving steroids for treatment of GVHD or for other reasons, dosage must have been tapered to ≤0.5mg/kg prednisone (or equivalent) prior to study enrollment. Patients may not have received ATG, or Campath or other immunosuppressive monoclonal antibodies in the last 28 days.
Not provided
Not provided
Not provided
Not provided
|
The efficacy of penta-STs will be determined based on the reconstitution of antiviral immunity (determination of virus-specific T cells) |
| 12 weeks post the last dose of penta-STs |
| Antifungal immunity | The efficacy of penta-STs will be determined based on reconstitution of antifungal immunity (determination of Aspergillus fumigatus-specific T cells) | 12 weeks post the last dose of penta-STs |
| Viral reactivations or recurrence of AF infection | The efficacy of penta-STs will be determined by the absence of viral reactivations or recurrence of AF infection post penta-STs infusion | 6 months post the last dose of penta-STs |
| Thessaloniki |
| 57010 |
| Greece |
| ID | Term |
|---|---|
| D000257 | Adenoviridae Infections |
| ID | Term |
|---|---|
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D007239 | Infections |
Not provided
Not provided